Open forum infectious diseases · 2026
Mycoplasma pneumoniae-associated Central Nervous System Manifestations: Current Knowledge and Challenges.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Akinnurun Oluwafemi M, Dumke Roger
Аннотация
BACKGROUND: Mycoplasma pneumoniae is a common cause of human respiratory infections. Extrapulmonary manifestations include diseases of the central nervous system (CNS).
METHODS: To summarize the current knowledge on M. pneumoniae-associated CNS complications, cases published in PubMed between 2015 and 2025 were reviewed.
RESULTS: We included 70 studies with 207 patients. Various neurological manifestations were identified, affecting patients between the ages of 3 and 69. Cases of encephalitis predominated (72%). Diagnosis of M. pneumoniae involvement was confirmed primarily by the detection of specific antibodies in serum. The prodromal phase between respiratory and neurological symptoms (<7 vs ≥ 7 days) was distributed almost evenly. In most cases, antibiotics effective against mycoplasma are used (88%), and in 81% of patients, complete recovery was achieved.
CONCLUSIONS: While the administration of antibiotics is accepted for the treatment of CNS manifestations, the use of other therapies is guided by the severity of the course and empirical considerations.
METHODS: To summarize the current knowledge on M. pneumoniae-associated CNS complications, cases published in PubMed between 2015 and 2025 were reviewed.
RESULTS: We included 70 studies with 207 patients. Various neurological manifestations were identified, affecting patients between the ages of 3 and 69. Cases of encephalitis predominated (72%). Diagnosis of M. pneumoniae involvement was confirmed primarily by the detection of specific antibodies in serum. The prodromal phase between respiratory and neurological symptoms (<7 vs ≥ 7 days) was distributed almost evenly. In most cases, antibiotics effective against mycoplasma are used (88%), and in 81% of patients, complete recovery was achieved.
CONCLUSIONS: While the administration of antibiotics is accepted for the treatment of CNS manifestations, the use of other therapies is guided by the severity of the course and empirical considerations.